본문 바로가기
KERD
논문KCI 등재

Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy

이병하|Wolfarth Alexandra A.|Dhar Swati|Goon Jack B.|Ezeanya Ugonna I.|Ferrando-Martínez Sara
대한면역학회 (The Korean Association of Immunologists)|2022.02|Immune Network|제22권 제1호|pp. 1-22|DOI 10.4110/in.2022.22.e5

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

CancerCytokinesIL-2ImmunotherapyIL-7

초록

The approval of immunotherapies such as checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines has revolutionized the way cancer treatment is approached. While immunotherapies have improved clinical outcome in a variety of tumor types, some cancers have proven harder to combat using single agents, underscoring the need for multi-targeted immunotherapy approaches. Efficacy of CPIs and cancer vaccines requires patients to have a competent immune system with adequate cell numbers while the efficacy of adoptive cellular therapy is limited by the expansion and persistence of cells after infusion. A promising strategy to overcome these challenges is combination treatment with common gamma-chain cytokines. Gamma-chain cytokines play a critical role in the survival, proliferation, differentiation and function of multiple immune cell types, including CD8 T-cells and NK cells, which are at the center of the anti-tumor response. While the short half-life of recombinant cytokines initially limited their application in the clinic, advancements in protein engineering have led to the development of several next-generation drug candidates with dramatically increased half-life and bioactivity. When combining these cytokines with other immunotherapies, strong evidence of synergy has been observed in preclinical and clinical cancer settings. This promising data has led to the initiation of 70 ongoing clinical trials including IL-2, IL-7, IL-15 and IL-21. This review summarizes the recent advancements of common gamma-chain cytokines and their potential as a cancer immunotherapy.

Abstract

The approval of immunotherapies such as checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines has revolutionized the way cancer treatment is approached. While immunotherapies have improved clinical outcome in a variety of tumor types, some cancers have proven harder to combat using single agents, underscoring the need for multi-targeted immunotherapy approaches. Efficacy of CPIs and cancer vaccines requires patients to have a competent immune system with adequate cell numbers while the efficacy of adoptive cellular therapy is limited by the expansion and persistence of cells after infusion. A promising strategy to overcome these challenges is combination treatment with common gamma-chain cytokines. Gamma-chain cytokines play a critical role in the survival, proliferation, differentiation and function of multiple immune cell types, including CD8 T-cells and NK cells, which are at the center of the anti-tumor response. While the short half-life of recombinant cytokines initially limited their application in the clinic, advancements in protein engineering have led to the development of several next-generation drug candidates with dramatically increased half-life and bioactivity. When combining these cytokines with other immunotherapies, strong evidence of synergy has been observed in preclinical and clinical cancer settings. This promising data has led to the initiation of 70 ongoing clinical trials including IL-2, IL-7, IL-15 and IL-21. This review summarizes the recent advancements of common gamma-chain cytokines and their potential as a cancer immunotherapy.

참고문헌 (116)

  1. Meyers DE, "Biomarkers of immune checkpoint inhibitor efficacy in cancer", Curr Oncol, 27, pp.S106~S114 (2020)
  2. McLellan AD, "Chimeric antigen receptor T cell persistence and memory cell formation", Immunol Cell Biol, 97, pp.664~674 (2019)
  3. Bowen WS, "Current challenges for cancer vaccine adjuvant development", Expert Rev Vaccines, 17, pp.207~215 (2018)
  4. Lin JX, "The common cytokine receptor γ chain family of cytokines", Cold Spring Harb Perspect Biol, 10, pp.a028449~ (2018)
  5. Raeber ME, "The role of cytokines in T-cell memory in health and disease", Immunol Rev, 283, pp.176~193 (2018)
  6. Leonard WJ, "The γc family of cytokines : basic biology to therapeutic ramifications", Immunity, 50, pp.832~850 (2019)
  7. Waldmann TA, "The multi-subunit interleukin-2 receptor", Annu Rev Biochem, 58, pp.875~911 (1989)
  8. Xue D, "Next-generation cytokines for cancer immunotherapy", Antib Ther, 4, pp.123~133 (2021)
  9. Fyfe G, "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy", J Clin Oncol, 13, pp.688~696 (1995)
  10. Atkins MB, "High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma : analysis of 270 patients treated between 1985 and 1993", J Clin Oncol, 17, pp.2105~2116 (1999)
  11. Fisher RI, "Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma", Cancer J Sci Am, 6(Suppl 1), pp.S55~S57 (2000)
  12. "Proleukin® (aldesleukin)"[URL]
  13. Kolb HC, "Click chemistry : diverse chemical function from a few good reactions", Angew Chem Int Ed Engl, 40, pp.2004~2021 (2001)
  14. Ptacin JL, "An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism", Nat Commun, 12, pp.4785~ (2021)
  15. Milla ME, "1225P-THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome(VLS)", Ann Oncol, 30, pp.v501~ (2019)
  16. Filip Janku RA, "multicenter phase 1", 2 study, 2021, pp.81, LB041~
  17. Charych DH, "NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models", Clin Cancer Res, 22, pp.680~690 (2016)
  18. Bentebibel SE, "A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors", Cancer Discov, 9, pp.711~721 (2019)
  19. Lopes JE, "ALKS 4230 : a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy", J Immunother Cancer, 8, pp.e000673~ (2020)
  20. Lopes JE, "Pharmacokinetics and pharmacodynamic effects of nemvaleukin alfa, a selective agonist of the intermediate-affinity IL-2 receptor, in cynomolgus monkeys", J Pharmacol Exp Ther, 379, pp.203~210 (2021)
  21. Castellani P, "The fibronectin isoform containing the ED-B oncofetal domain : a marker of angiogenesis", Int J Cancer, 59, pp.612~618 (1994)
  22. Lieverse RI, "Human fibronectin extra domain B as a biomarker for targeted therapy in cancer", Mol Oncol, 14, pp.1555~1568 (2020)
  23. Johannsen M, "The tumour-targeting human L19-IL2 immunocytokine : preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma", Eur J Cancer, 46, pp.2926~2935 (2010)
  24. Ongaro T, "A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo", Oncotarget, 11, pp.3698~3711 (2020)
  25. Osenga KL, "A phase I clinical trial of the hu14. 18-IL2(EMD 273063)as a treatment for children with refractory or recurrent neuroblastoma and melanoma : a study of the Children’s Oncology Group", Clin Cancer Res, 12, pp.1750~1759 (2006)
  26. Albertini MR, "Phase II trial of hu14. 18-IL2 for patients with metastatic melanoma", Cancer Immunol Immunother, 61, pp.2261~2271 (2012)
  27. Shusterman S, "Antitumor activity of hu14. 18-IL2 in patients with relapsed", refractory neuroblastoma : a Children’s Oncology Group(COG)phase II study, 2010, pp.28, 4969~4975
  28. Albertini MR, "Pilot trial of the hu14. 18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma", Cancer Immunol Immunother, 67, pp.1647~1658 (2018)
  29. Sharma P, "Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275) : a multicentre, single-arm, phase 2 trial", Lancet Oncol, 18, pp.312~322 (2017)
  30. Huddart RA, "PIVOT-10 : Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer", Future Oncol, 17, pp.137~149 (2021)
  31. Waldhauer I, "Simlukafusp alfa(FAP-IL2v)immunocytokine is a versatile combination partner for cancer immunotherapy", MAbs, 13, pp.1913791~ (2021)
  32. Italiano A, "Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer", J Clin Oncol, 39(15_suppl), pp.5510~ (2021)
  33. Pyo KH, "Abstract 1826 : Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target", Cancer Res, 81, pp.1826~ (2021)
  34. Pyo KH, "Abstract 6529 : GI101, A novel CD80-IgG4-IL2 variant bispecific protein, inhibits tumor growth and induces anti-tumor immune response in multiple preclinical models", Cancer Res, 80, pp.6529~ (2020)
  35. Cho BC, "470 A phase 1", 2, openlabel, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors(KEYNOTE-B59), 2021, pp.9(Suppl 2), A499~
  36. Mahmoudpour SH, "Safety of low-dose subcutaneous recombinant interleukin-2 : systematic review and meta-analysis of randomized controlled trials", Sci Rep, 9, pp.7145~ (2019)
  37. Khammari A, "Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection : results from a multicentre, randomized clinical phase III trial", Cancer Immunol Immunother, 69, pp.1663~1672 (2020)
  38. Nguyen LT, "Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2", Cancer Immunol Immunother, 68, pp.773~785 (2019)
  39. Dréno B, "Phase I", II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients, 2021, pp.70, 3015~3030
  40. Parisi G, "Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist", Nat Commun, 11, pp.660~ (2020)
  41. Camisaschi C, "Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides : impact on the antigen-specific T cell response", Cancer Immunol Immunother, 62, pp.897~908 (2013)
  42. Filipazzi P, "Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides", Clin Cancer Res, 18, pp.6485~6496 (2012)
  43. Rahma OE, "The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors", J Transl Med, 12, pp.55~ (2014)
  44. Baek S, "Therapeutic DC vaccination with IL-2as a consolidation therapy for ovarian cancer patients : a phase I", II trial, 2015, pp.12, 87~95
  45. Tanyi JL, "Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer", NPJ Vaccines, 6, pp.36~ (2021)
  46. Mazzucchelli R, "Interleukin-7 receptor expression : intelligent design", Nat Rev Immunol, 7, pp.144~154 (2007)
  47. Pulliam SR, "Common gamma chain cytokines in combinatorial immune strategies against cancer", Immunol Lett, 169, pp.61~72 (2016)
  48. Onder L, "IL-7-producing stromal cells are critical for lymph node remodeling", Blood, 120, pp.4675~4683 (2012)
  49. Zaunders JJ, "Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses", Cytokine Growth Factor Rev, 25, pp.391~401 (2014)
  50. Sportès C, "Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy", Clin Cancer Res, 16, pp.727~735 (2010)
  51. Perales MA, "Recombinant human interleukin-7(CYT107)promotes T-cell recovery after allogeneic stem cell transplantation", Blood, 120, pp.4882~4891 (2012)
  52. Trédan O, "ELYPSE-7 : a randomized placebo-controlled phase IIa trial with CYT107exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients", Ann Oncol, 26, pp.1353~1362 (2015)
  53. Lee SW, "hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects", Clin Transl Sci, 13, pp.1161~1169 (2020)
  54. Kim JH, "Hybrid Fcfused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy", Clin Transl Immunology, 9, pp.e1168~ (2020)
  55. Heo M, "P425 Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers", Proceedings of the Society for Immunotherapy of Cancer (SITC) 2019, pp.282~ (2019), SITC
  56. Campian JL, "Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models", Clin Cancer Res (2022)
  57. Zhou A, "396 NTI7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation", J Immunother Cancer, 9(Suppl 2), pp.A428~ (2021)
  58. Sohn J, "322 Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b", 2 KEYNOTE-899 Study, 2020, pp.8(Suppl 3), A197~A198
  59. Kim R, "404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab : cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer", J Immunother Cancer, 9(Suppl 2), pp.A435~ (2021)
  60. Naing A, "408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab : cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer", J Immunother Cancer, 9(Suppl 2), pp.A439~ (2021)
  61. Stock S, "Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy", Int J Mol Sci, 20, pp.6223~ (2019)
  62. Adachi K, "IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor", Nat Biotechnol, 36, pp.346~351 (2018)
  63. He C, "Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion", Cancers(Basel), 12, pp.1969~ (2020)
  64. Luo H, "Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion", Clin Cancer Res, 26, pp.5494~5505 (2020)
  65. Pang N, "IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin", J Hematol Oncol, 14, pp.118~ (2021)
  66. Ding ZC, "Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells", Sci Rep, 7, pp.12168~ (2017)
  67. Kim MY, "A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence and anti-tumor activity", Nat Commun (2022)
  68. Choi YW, "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells", Clin Cancer Res, 22, pp.5898~5908 (2016)
  69. Gu YZ, "Forced coexpression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity", Sci Rep, 6, pp.32351~ (2016)
  70. Merchant MS, "Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas", Clin Cancer Res, 22, pp.3182~3191 (2016)
  71. Pachynski RK, "IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer(mCRPC)", J Immunother Cancer, 9, pp.e002903~ (2021)
  72. Isvoranu G, "Therapeutic potential of interleukin-15 in cancer(review)", Exp Ther Med, 22, pp.675~ (2021)
  73. Waldmann TA, "The biology of interleukin-2 and interleukin-15 : implications for cancer therapy and vaccine design", Nat Rev Immunol, 6, pp.595~601 (2006)
  74. Bergamaschi C, "Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity", J Biol Chem, 283, pp.4189~4199 (2008)
  75. Waickman AT, "CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans", Cytokine, 99, pp.266~274 (2017)
  76. Conlon KC, "Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer", J Clin Oncol, 33, pp.74~82 (2015)
  77. Miller JS, "A first-in-human phase I study of subcutaneous outpatient recombinant human IL15(rhIL15)in adults with advanced solid tumors", Clin Cancer Res, 24, pp.1525~1535 (2018)
  78. Liu B, "A novel fusion of ALT-803(interleukin(IL)-15 superagonist)with an antibody demonstrates antigen-specific antitumor responses", J Biol Chem, 291, pp.23869~23881 (2016)
  79. Romee R, "First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803to treat relapse after transplantation", Blood, 131, pp.2515~2527 (2018)
  80. Kim PS, "IL-15 superagonist", IL-15RαSushi-Fc fusion complex(IL-15SA, Oncotarget, pp.2016, 7[DOI]
  81. Margolin K, "Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors", Clin Cancer Res, 24, pp.5552~5561 (2018)
  82. Knudson KM, "Rationale for IL-15 superagonists in cancer immunotherapy", Expert Opin Biol Ther, 20, pp.705~709 (2020)
  83. Miyazaki T, "Pharmacokinetic and pharmacodynamic study of NKTR-255, a polymer-conjugated human IL-15, in cynomolgus monkey", Blood, 132, pp.2952~ (2018)
  84. Wrangle JM, "ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer : a non-randomised, open-label, phase 1b trial", Lancet Oncol, 19, pp.694~704 (2018)
  85. Knudson KM, "Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1", IL-15 superagonist, 2020, pp.8, e000493~
  86. Desbois M, "IL-15 trans-signaling with the superagonist RLI promotes effector", memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists, 2016, pp.197, 168~178
  87. Pérez-Martínez A, "A phase I", II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors, 2015, pp.17, 1594~1603
  88. Shah NN, "Acute GVHD in patients receiving IL-15", 4-1BBL activated NK cells following T-cell-depleted stem cell transplantation, 2015, pp.125, 784~792
  89. Giuffrida L, "IL-15 preconditioning augments CAR T Cell responses to checkpoint blockade for improved treatment of solid tumors", Mol Ther, 28, pp.2379~2393 (2020)
  90. Liu E, "Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors", N Engl J Med, 382, pp.545~553 (2020)
  91. Heczey A, "Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma : an interim analysis", Nat Med, 26, pp.1686~1690 (2020)
  92. Fabian KP, "PD-L1 targeting high-affinity NK(t-haNK)cells induce direct antitumor effects and target suppressive MDSC populations", J Immunother Cancer, 8, pp.e000450~ (2020)
  93. Chu Y, "Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma", J Immunother Cancer, 8, pp.e001238~ (2020)
  94. Rosser CJ, "Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue(N-803)admixed with Bacillus Calmette-Guérin(BCG)for the treatment of bladder cancer", OncoImmunology, 10, pp.1912885~ (2021)
  95. Do-Thi VA, "IL-15Rα-secreting cell-based cancer vaccine using a baculovirus system", Cancers(Basel), 13, pp.4039~ (2021)
  96. 김동현, "Induction of Unique STAT Heterodimers by IL-21 Provokes IL-1RI Expression on CD8 + T Cells, Resulting in Enhanced IL-1β Dependent Effector Function", Immune Network, 21(5), pp.1~19 (2021), 대한면역학회[DOI]
  97. Davis MR, "The role of IL-21 in immunity and cancer", Cancer Lett, 358, pp.107~114 (2015)
  98. Davis ID, "An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma", Clin Cancer Res, 13, pp.3630~3636 (2007)
  99. Petrella TM, "Final efficacy results of a randomized phase II study of recombinant interleukin-21 compared to dacarbazine in patients with recurrent or metastatic melanoma", J Oncol Res Treat, 4, pp.10001322019~ (2019)
  100. Thompson JA, "Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma", J Clin Oncol, 26, pp.2034~2039 (2008)
  101. Bhatt S, "Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-celldependent cytotoxicity", Blood, 129, pp.2246~2256 (2017)
  102. Liu H, "An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade", Int Immunopharmacol, 101, pp.108307~ (2021)
  103. Williams P, "A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo", Mol Ther, 18, pp.1293~1301 (2010)
  104. Uricoli B, "Engineered cytokines for cancer and autoimmune disease immunotherapy", Adv Healthc Mater, 10, pp.e2002214~ (2021)
  105. Deng S, "Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells", JCI Insight, 5, pp.e132000~ (2020)
  106. Lewis KE, "Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models", Oncoimmunology, 7, pp.e1377873~ (2017)
  107. Seo H, "IL21 therapy combined with PD-1 and Tim-3blockade provides enhanced NK cell antitumor activity against MHC class I-deficient tumors", Cancer Immunol Res, 6, pp.685~695 (2018)
  108. Li Y, "Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy", Nat Commun, 12, pp.951~ (2021)
  109. Chapuis AG, "Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients", Sci Transl Med, 5, pp.174~ (2013)
  110. Chapuis AG, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient", J Exp Med, 213, pp.1133~1139 (2016)
  111. Peng J, "Irradiated bladder cancer cells expressing both GM-CSF and IL-21 versus either GM-CSF or IL-21 alone as tumor vaccine in a mouse xenograft model", BioMed Res Int, 2019, pp.8262989~ (2019)
  112. He X, "ESAT-6-gpi DNA vaccine augmented the specific antitumour efficacy induced by the tumour vaccine B16F10-ESAT-6-gpi", IL-21 in a mouse model, 2013, pp.78, 69~78
  113. Kefaloyianni E, "Soluble forms of cytokine and growth factor receptors : mechanisms of generation and modes of action in the regulation of local and systemic inflammation", FEBS Lett (2022)[DOI]
  114. Van Anh Do-Thi, "Crosstalk between the Producers and Immune Targets of IL-9", Immune Network, 20(6), pp.1~16 (2020), 대한면역학회[DOI]
  115. Li Z, "Paradoxical roles of IL-4 in tumor immunity", Cell Mol Immunol, 6, pp.415~422 (2009)
  116. Wan J, "IL-9 and IL-9-producing cells in tumor immunity", Cell Commun Signal, 18, pp.50~ (2020)

관련 논문AI추천

Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7김지혜, 이건주, Seung-Woo Lee생화학분자생물학회 · BMB Reports2021 · 제54권 제1호Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy장미희, Bryan Marr, Donghyeon Jo, Seung-Hwan Lee대한면역학회 · Immune Network2025 · 제25권 제2호Optimising IL-2 for Cancer ImmunotherapyJonathan Sprent, Onur Boyman대한면역학회 · Immune Network2024 · 제24권 제1호Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends임세진, Ha Sang-Jun, Lee Kyungmin생화학분자생물학회 · Experimental and Molecular Medicine2024 · 제56권 Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical ImmunotherapiesChanghyung Lee, Donghoon Choi, Jung-Hyun Park, Seung-Woo Lee, Young Chul Sung대한면역학회 · Immune Network2024 · 제24권 제1호NK Cell-Based Immunotherapies in Cancer김성진, 신민화, 이경미, Junghee Kim, Jungwon Kim, Siyoung A. Lim대한면역학회 · Immune Network2020 · 제20권 제2호

이 간행물의 다른 논문 (12건)

Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside김혜영, 신재우, 고병철, 함종호pp. 1-26Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research이상일, 김민교, 채용호pp. 1-20CAR T Cell Immunotherapy Beyond Haematological Malignancy김효진, 김찬혁, Hupperetz Cedric, Lah Sangjoonpp. 1-19Targeted Immunotherapy for Autoimmune Disease김완욱, 정승민pp. 1-23Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy김혜련, 하상준, 이지범pp. 1-22
원문 보기